188
Participants
Start Date
June 13, 2011
Primary Completion Date
June 28, 2019
Study Completion Date
June 28, 2019
MEDI-573
Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Aromatase Inhibitor
Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Research Site, Brussels
Research Site, Edegem
Research Site, Brasschaat
Research Site, Miskolc
Research Site, Nyíregyháza
Research Site, Mons
Research Site, Bruges
Research Site, Barcelona
Research Site, Leuven
Research Site, Aalst
Research Site, Lake Success
Research Site, Lake Success
Research Site, Nassau
Research Site, Bethesda
Research Site, Rockville
Research Site, Baltimore
Research Site, Baltimore
Research Site, Frederick
Research Site, Richmond
Research Site, Madrid
Research Site, Madrid
Research Site, Málaga
Research Site, Lawrenceville
Research Site, Athens
Research Site, Augusta
Research Site, Orlando
Research Site, St. Petersburg
Research Site, Fort Myers
Research Site, Montpellier
Research Site, Haifa
Research Site, Nashville
Research Site, Memphis
Research Site, Toledo
Research Site, Cleveland
Research Site, Dortmund
Research Site, Cleveland
Research Site, Canton
Research Site, Middletown
Research Site, Cincinnati
Research Site, Lansing
Research Site, Petah Tikva
Research Site, Ramat Gan
Research Site, Rochester
Research Site, Witten
Research Site, Frankfurt
Research Site, Tel Aviv
Research Site, Ẕerifin
Research Site, Le Mans
Research Site, Rehovot
Research Site, Houston
Research Site, Lubbock
Research Site, München
Research Site, Scottsdale
Research Site, Albuquerque
Research Site, Bakersfield
Research Site, Pleasant Hill
Research Site, Stamford
Research Site, Port Saint Lucie
Research Site, Scarborough
Research Site, Ann Arbor
Research Site, Oshawa
Research Site, Ottawa
Research Site, Montreal
Research Site, Lodz
Research Site, Barcelona
Research Site, Barcelona
Research Site, Cardiff
Research Site, London
Research Site, Southampton
Research Site, Stoke-on-Trent
Research Site, Wolverhampton
Lead Sponsor
MedImmune LLC
INDUSTRY